Wells Fargo & Company Avrobio, Inc. Transaction History

Wells Fargo & Company

$407 Billion
Q2 2024

17 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 10, 2024	SELL	$1.15 - $1.48 $10,006 - $12,877	-8,701 Reduced 6.47%	125,753 $160,000
Q4 2023 Feb 09, 2024	SELL	$1.22 - $1.62 $17,266 - $22,927	-14,153 Reduced 9.52%	134,454 $182,000
Q3 2023 Nov 13, 2023	SELL	$0.98 - $1.62 $18,117 - $29,948	-18,487 Reduced 11.06%	148,607 $228,000
Q2 2023 Aug 15, 2023	BUY	$0.58 - $1.31 $17,417 - $39,339	30,030 Added 21.91%	167,094 $158,000
Q1 2023 May 12, 2023	BUY	$0.76 - $1.82 $36,177 - $86,635	47,602 Added 53.21%	137,064 $137,000
Q4 2022 Feb 13, 2023	SELL	$0.64 - $0.91 $3,543 - $5,038	-5,537 Reduced 5.83%	89,462 $63,000
Q3 2022 Nov 14, 2022	BUY	$0.68 - $1.11 $3,055 - $4,988	4,494 Added 4.97%	94,999 $61,000
Q2 2022 Aug 12, 2022	BUY	$0.75 - $1.33 $701 - $1,243	935 Added 1.04%	90,505 $83,000
Q1 2022 May 16, 2022	SELL	$1.29 - $4.04 $3,059 - $9,582	-2,372 Reduced 2.58%	89,570 $118,000
Q4 2021 Feb 14, 2022	BUY	$3.45 - $6.05 $115,392 - $202,354	33,447 Added 57.18%	91,942 $354,000
Q3 2021 Nov 15, 2021	SELL	$5.53 - $9.28 $21,019 - $35,273	-3,801 Reduced 6.1%	58,495 $327,000
Q2 2021 Aug 16, 2021	SELL	$7.84 - $12.6 $86,961 - $139,759	-11,092 Reduced 15.11%	62,296 $554,000
Q1 2021 May 13, 2021	SELL	$10.54 - $19.3 $52,721 - $96,538	-5,002 Reduced 6.38%	73,388 $931,000
Q4 2020 Feb 09, 2021	BUY	$12.79 - $17.1 $729,950 - $975,931	57,072 Added 267.72%	78,390 $1.09 Million
Q3 2020 Nov 05, 2020	SELL	$12.99 - $19.41 $549,191 - $820,615	-42,278 Reduced 66.48%	21,318 $278,000
Q2 2020 Aug 13, 2020	BUY	$12.19 - $22.96 $414,508 - $780,731	34,004 Added 114.91%	63,596 $1.11 Million
Q1 2020 May 14, 2020	BUY	$10.08 - $27.21 $298,287 - $805,198	29,592 New	29,592 $460,000

Others Institutions Holding AVRO

# of Institutions

Shares Held

559K

Call Options Held

Put Options Held

View Full List

About AVROBIO, Inc.

Ticker AVRO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,773,900
Description
AVROBIO, Inc., a clinical-stage gene therapy company, develops ex vivo lentiviral-based gene therapies to treat rare diseases following a single dose worldwide. Its gene therapies employ hematopoietic stem cells that are collected from patients and modified with a lentiviral vector to insert functional copies of the gene that is defective in the...

More about AVRO

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Wells Fargo & Company, based on Form 13F filings with the SEC.

News

Stay updated on Wells Fargo & Company with notifications on news.

Account